Compare AUDC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | ACIU |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.9M | 288.0M |
| IPO Year | 2000 | 2015 |
| Metric | AUDC | ACIU |
|---|---|---|
| Price | $9.12 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.50 | $10.00 |
| AVG Volume (30 Days) | 109.8K | ★ 255.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | $706.75 |
| Revenue Next Year | $2.18 | $321.13 |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $1.60 |
| 52 Week High | $11.48 | $4.00 |
| Indicator | AUDC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 46.57 |
| Support Level | $8.46 | $2.58 |
| Resistance Level | $9.82 | $2.99 |
| Average True Range (ATR) | 0.33 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 94.55 | 37.00 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.